keyword
MENU ▼
Read by QxMD icon Read
search

Brimonidine

keyword
https://www.readbyqxmd.com/read/29762267/the-more-the-better-the-usefulness-of-brimonidine-as-the-fourth-anti-glaucoma-eye-drop
#1
Tomas Bro, Christina Lindén
PURPOSE: To study the intraocular pressure (IOP)-lowering effect of adding brimonidine as the fourth anti-glaucoma medication to a pre-existing therapy of three topical drugs. METHODS: A retrospective, register-based, cohort study of medical records and computerized medical information comprising one county in Sweden. The main outcome measure was change in IOP after brimonidine addition. Short- and long-term effects were evaluated. RESULTS: Out of 4910 patients on anti-glaucoma medication, 69 (1...
May 12, 2018: Journal of Glaucoma
https://www.readbyqxmd.com/read/29680880/a-phase-iii-randomized-clinical-trial-of-a-0-5-timolol-0-2-brimonidine-2-0-dorzolamide-fixed-combination-preservative-free-ophthalmic-solution-vs-0-5-timolol-0-2-brimonidine-2-0-dorzolamide-fixed-combination-in-patients-with-controlled-primary-open-angle-glaucoma
#2
Francisco Gómez-Aguayo, José A Paczka, Rubén Leñero-Córdova, Jesús Jiménez-Román, Jaime Davila-Villarreal, Curt Hartleben, Leopoldo Baiza-Durán, Oscar Olvera-Montaño, Francisco García-Velez, Patricia Muñoz-Villegas
INTRODUCTION: The aim of this prospective crossover study was to evaluate the non-inferiority of PRO-122 (a preservative-free fixed combination) compared with 0.5% timolol + 0.2% brimonidine + 2.0% dorzolamide fixed combination (KOF) by evaluating its efficacy, tolerability and safety in subjects with controlled primary open-angle glaucoma (POAG) previously treated with KOF for at least 2 months. METHODS: In a prospective, crossover, randomized, double-masked multicenter study, patients previously treated with KOF were randomly assigned to receive either PRO-122 or KOF for 30 days...
April 21, 2018: Ophthalmology and Therapy
https://www.readbyqxmd.com/read/29613980/use-of-intravitreal-bevacizumab-for-the-treatment-of-secondary-glaucoma-due-to-metastatic-iris-tumor
#3
Rukiye Aydin, Tongalp H Tezel
PURPOSE: To report the efficacy of intravitreal bevacizumab to resolve secondary angle closure glaucoma caused by biliary tract carcinoma metastasis to iris. ABSTRACT: A 52-year-old Caucasian woman who was under systemic chemotherapy for biliary tract carcinoma presented with metastatic tumor in the left iris. At presentation, her visual acuity was at 20/50 level. Tumor was occupying nasal half of the iris and had already occupied 5.5 clock hours of the angle resulting intraocular pressure elevation to 34▒mm Hg...
April 2, 2018: Journal of Glaucoma
https://www.readbyqxmd.com/read/29520478/increase-in-the-oct-angiographic-peripapillary-vessel-density-by-rock-inhibitor-ripasudil-instillation-a-comparison-with-brimonidine
#4
Etsuo Chihara, Galina Dimitrova, Tomoyuki Chihara
PURPOSE: To assess the responses of the superficial peripapillary retinal vessel density (VD) and prelaminar flow index (PLFI) to topical Rho-assisted coiled-coil forming protein kinase (ROCK) inhibitor ripasudil and alpha-2 agonist brimonidine using optical coherence tomography angiography. METHODS: This is a prospective, non-randomized, comparative cohort study. We studied the response of optical coherence tomography angiography (OCTA) parameters to drugs in 24 eyes treated with ripasudil and 23 eyes treated with brimonidine at the Sensho-kai Eye Institute...
March 8, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29479294/mildly-cross-linked-dendrimer-hydrogel-prepared-via-aza-michael-addition-reaction-for-topical-brimonidine-delivery
#5
Juan Wang, Geoffrey S Williamson, Michael G Lancina, Hu Yang
In this work, we developed a mildly cross-linked dendrimer hydrogel (mcDH) via aza -Michael addition of polyamidoamine (PAMAM) dendrimer G5 and polyethylene glycol diacrylate (PEG-DA, Mn =575 g/mol). We chose the antiglaucoma drug brimonidine tartrate as a model drug and developed a new antiglaucoma drug formulation on the basis of mcDH. Cytotoxicity of the mcDH formulation to NIH3T3 fibroblasts, in vitro drug release kinetics and ex vivo drug permeability across the rabbit cornea were examined. We also studied interactions between PAMAM dendrimer and the drug using 1 H NMR spectroscopy for a mechanistic understanding of brimonidine release from the mcDH...
December 2017: Journal of Biomedical Nanotechnology
https://www.readbyqxmd.com/read/29476924/branched-polyrotaxane-hydrogels-consisting-of-alpha-cyclodextrin-and-low-molecular-weight-four-arm-polyethylene-glycol-and-the-utility-of-their-thixotropic-property-for-controlled-drug-release
#6
Juan Wang, Geoffrey S Williamson, Hu Yang
In this work, we developed a new class of branched polyrotaxane hydrogel made of 4-arm polyethylene glycol (4-PEG) and α-cyclodextrin (α-CD) using supramolecular host-guest interactions as a cross-linking strategy. Because of the dynamic nature of the non-covalent host-guest cross-linking, the resulting supramolecular α-CD/4-PEG hydrogels show thixotropic behavior and undergo a reversible gel-sol transition in response to shear stress change. We loaded the antiglaucoma drug brimonidine into the α-CD/4-PEG gel and found the drug release kinetics was controlled by shear stress...
May 1, 2018: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29461408/brimonidine-ophthalmic-solution-0-025-for-reduction-of-ocular-redness-a-randomized-clinical-trial
#7
Eugene McLaurin, Megan E Cavet, Paul J Gomes, Joseph B Ciolino
SIGNIFICANCE: The α2-adrenergic receptor agonist brimonidine has been reported to induce conjunctival blanching in cataract, strabismus, laser refractive, and filtration procedures. Clinicians are often faced with red eyes with no apparent underlying pathology. Low-dose brimonidine reduced ocular redness in such subjects with efficacy maintained over 1 month and negligible rebound redness. PURPOSE: The aim of this study was to evaluate the safety and efficacy of brimonidine tartrate ophthalmic solution 0...
March 2018: Optometry and Vision Science: Official Publication of the American Academy of Optometry
https://www.readbyqxmd.com/read/29452108/effect-of-brimonidine-an-%C3%AE-2-adrenergic-agonist-on-human-meibomian-gland-epithelial-cells
#8
Xi Han, Yang Liu, Wendy R Kam, David A Sullivan
We recently discovered that the anti-glaucoma pharmaceuticals timolol, a β adrenergic antagonist, and pilocarpine, a cholinergic compound, negatively influence the morphology, proliferative capacity and survival of human meibomian gland epithelial cells (HMGECs). We hypothesize that another class of anti-glaucoma drugs, the α2 adrenergic agonists, also acts directly on HMGECs to affect their structure and function. We tested this hypothesis. Immortalized (i) HMGECs were cultured with brimonidine, as well as clonidine (α2 agonist), phenylephrine (α1 agonist), RX821002 (inverse α2 agonist) and MK912 (neutral α2 agonist) for up to 7 days...
May 2018: Experimental Eye Research
https://www.readbyqxmd.com/read/29374829/in-vitro-safety-pharmacology-profiling-of-topical-%C3%AE-adrenergic-agonist-treatments-for-erythema-of-rosacea
#9
David Piwnica, Atul Pathak, Gregor Schäfer, James R Docherty
BACKGROUND: Topical α-adrenergic agonist therapy has been developed to treat the persistent erythema of rosacea patients. Brimonidine and oxymetazoline are both topical α-adrenergic agonists. OBJECTIVES: The objective of this in vitro safety pharmacology study was to compare the potential safety profiles of brimonidine and oxymetazoline. METHODS: Brimonidine and oxymetazoline underwent pharmacological profiling with a standard panel of 151 assays, including α-adrenergic receptors and 5-hydroxytryptamine (5-HT) receptors...
March 2018: Drugs in R&D
https://www.readbyqxmd.com/read/29310481/nanostructured-lipid-carriers-for-intraocular-brimonidine-localisation-development-in-vitro-and-in-vivo-evaluation
#10
Noha S El-Salamouni, Ragwa M Farid, Amal H El-Kamel, Safaa S El-Gamal
Brimonidine ocular hypotensive effect can be enhanced by increasing residence time and corneal penetration. The current work aimed to formulate, evaluate and compare nanostructured lipid carriers (NLCs) to solid lipid nanoparticles (SLNs) and commercial eye drops for controlled brimonidine delivery. NLCs prepared by modified high shear homogenisation were spherical with a mean size of 151.97 ± 1.98 nm, negative zeta potential (ZP) of -44.2 ± 7.81 mV, % entrapment efficiency (EE) of 83.631 ± 0...
January 2018: Journal of Microencapsulation
https://www.readbyqxmd.com/read/29297751/the-efficacy-and-safety-of-the-fixed-combination-of-brinzolamide-1-and-brimonidine-0-2-in-normal-tension-glaucoma-an-18-month-retrospective-study
#11
Sang Wook Jin, Sae Mi Lee
PURPOSE: To evaluate efficacy and safety of brinzolamide (1%)/brimonidine (0.2%) fixed combination (BBFC) in normal tension glaucoma (NTG). METHODS: This retrospective study included NTG patients treated with BBFC as their primary therapy, NTG patients who had changed their medication to BBFC from brinzolamide or brimonidine, and NTG patients who had changed their medication to BBFC from concomitantly using brinzolamide and brimonidine. The intraocular pressure (IOP), mean deviation value, and adverse drug reactions were evaluated...
April 2018: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29228819/formulation-and-ex-vivo-in-vivo-evaluation-of-ph-triggered-brimonidine-tartrate-in-situ-gel-for-the-glaucoma-treatment-using-application-of-3-2-factorial-design
#12
Rohan K Barse, Amol A Tagalpallewar, Chandrakant R Kokare, Jaya P Sharma, Pankaj K Sharma
CONTEXT: Short residence time, poor bioavailability and poor permeability are the major problems for conventional eye drops treatment. OBJECTIVE: The aim of this article is to develop, optimize and ex vivo-in vivo investigation of brimonidine tartrate in situ gel as compared to marketed eye drops for the treatment of glaucoma. MATERIALS AND METHODS: The effect of independent variables, namely concentrations of polymers, on various dependent variables like viscosity at physiological pH and in vitro drug release were studied by using 32 factorial design...
May 2018: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/29204068/%C3%AE-adrenergic-agonist-brimonidine-control-of-experimentally-induced-myopia-in-guinea-pigs-a-pilot-study
#13
Yan Liu, Yuexin Wang, Huibin Lv, Xiaodan Jiang, Mingzhou Zhang, Xuemin Li
Purpose: To investigate the efficacy of α-adrenergic agonist brimonidine either alone or combined with pirenzepine for inhibiting progressing myopia in guinea pig lens-myopia-induced models. Methods: Thirty-six guinea pigs were randomly divided into six groups: Group A received 2% pirenzepine, Group B received 0.2% brimonidine, Group C received 0.1% brimonidine, Group D received 2% pirenzepine + 0.2% brimonidine, Group E received 2% pirenzepine + 0.1% brimonidine, and Group F received the medium...
2017: Molecular Vision
https://www.readbyqxmd.com/read/29164631/effects-of-selective-%C3%AE-2-adrenergic-receptor-agonists-on-electrical-field-stimulated-contractions-of-isolated-bronchi-in-horses
#14
A Menozzi, C Pozzoli, E Poli, C Colla, G Placenza, S Bertini
We investigated the effects of different selective α2 -adrenergic receptor (AR) agonists (detomidine, medetomidine, xylazine, and brimonidine) on the contractions of horse-isolated bronchi induced by electrical field stimulation (EFS) and by carbachol. No effects were observed on the contraction induced by carbachol, while α2 -AR agonists reduced EFS-evoked contractions in a concentration-related fashion. The rank order of potency (pD2 ) was brimonidine (7.40 ± 0.20) >medetomidine (7.09 ± 0.24) >detomidine (6...
April 2018: Journal of Veterinary Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29159432/comparison-of-the-neuroprotective-effects-of-brimonidine-tartrate-and-melatonin-on-retinal-ganglion-cells
#15
Deniz Marangoz, Elif Guzel, Signem Eyuboglu, Asli Gumusel, Ismail Seckin, Ferda Ciftci, Bayram Yilmaz, Ilgaz Yalvac
PURPOSE: We aimed to compare the neuroprotective effects of brimonidine tartrate (BRT) and melatonin (MEL) on retinal ganglion cells (RGCs) in a rat glaucoma model. METHODS: Thirty-six adult Wistar albino rats were allocated into six groups: control (C), glaucoma (G), BRT, MEL, G + BRT and G + MEL. After establishing the glaucoma model, intraocular pressure (IOP) of all animals measured at day 4 and day 30 was compared statistically with day 0 and day 4, respectively...
November 20, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/29152562/fast-dissolving-dendrimer-nanofiber-mats-as-alternative-to-eye-drops-for-more-efficient-antiglaucoma-drug-delivery
#16
Michael G Lancina, Sudha Singh, Uday B Kompella, Shahid Husain, Hu Yang
Polyamidoamine (PAMAM) dendrimers have been investigated as a potential platform for a number of ocular drugs, but only in aqueous solution. In this work we have developed fast dissolving dendrimer-based nanofibers (DNF) as a topical delivery vehicle for the glaucoma drug brimonidine tartrate (BT). The safety and drug release kinetics of these nanofiber mats were evaluated in vitro and in vivo. DNF caused no toxicity at therapeutic levels in cultured cells or ocular irritation in animal tests using a normotensive rat model...
August 14, 2017: ACS Biomaterials Science & Engineering
https://www.readbyqxmd.com/read/29151684/glaucoma-medication-preferences-among-glaucoma-specialists-in-mexico
#17
Gabriel Lazcano-Gomez, Daniela Alvarez-Ascencio, Cindy Haro-Zuno, Mauricio Turati-Acosta, Magdalena Garcia-Huerta, Jesus Jimenez-Arroyo, Rafael Castañeda-Diez, Armando Castillejos-Chevez, Roberto Gonzalez-Salinas, Francisca Dominguez-Dueñas, Jesus Jimenez-Roman
Aim: To determine the glaucoma specialists' preferences for the different brands of topical glaucoma medications available in Mexico. Materials and methods: A web-based survey was sent to 150 board-certified glaucoma specialists in Mexico, with 14 questions related to brand preferences for all glaucoma medications available in Mexico. Participants were asked to select each glaucoma medication class by brand and to state the factors leading to their choice. Results: Data from 111 (74%) glaucoma specialists were collected...
September 2017: Journal of Current Glaucoma Practice
https://www.readbyqxmd.com/read/29135708/high-permeability-and-intercellular-space-widening-with-brimonidine-tartrate-eye-drops-in-cultured-stratified-human-corneal-epithelial-sheets
#18
Yumi Hashimoto, Seiichi Yokoo, Tomohiko Usui, Yukiko Tsubota, Satoru Yamagami
PURPOSE: To investigate the toxicity of topical glaucoma medications using cultured stratified human corneal epithelial sheets (HCES). METHODS: HCES were exposed for 30 minutes to the following glaucoma medications: 0.1% brimonidine with sodium chlorite as the preservative, 0.005% latanoprost with 0.02% benzalkonium chloride (BAC) as the preservative, and 0.5% timolol with 0.005% BAC as the preservative. Then, cell viability and barrier function were tested by the WST-1 assay and carboxyfluorescein permeability assay, respectively...
February 2018: Cornea
https://www.readbyqxmd.com/read/29120262/evaluation-of-efficacy-and-safety-of-brimonidine-tartrate-ophthalmic-solution-0-025-for-treatment-of-ocular-redness
#19
Gail L Torkildsen, Christine M Sanfilippo, Heleen H DeCory, Paul J Gomes
Purpose/Aims: This study assessed the efficacy and safety of brimonidine tartrate ophthalmic solution, 0.025% for treating ocular redness in adult subjects. MATERIALS AND METHODS: This was a single-center, double-masked, randomized, vehicle-controlled, parallel-group study in subjects ≥40 years, with ocular redness. Subjects were randomized 2:1 to brimonidine or vehicle, instilled QID for four weeks. Subjects completed four visits, the last occurring one week after treatment discontinuation...
January 2018: Current Eye Research
https://www.readbyqxmd.com/read/29104721/topical-a-agonist-therapy-for-persistent-facial-erythema-of-rosacea-and-the-addition-of-oxmetazoline-to-the-treatment-armamentarium-where-are-we-now
#20
REVIEW
James Q Del Rosso
The presence of vasoactivity in rosacea-affected skin led to the development of two topical α-adrenergic receptor agonists, brimonidine tartrate 0.5% gel and oxymetazoline hydrochloride 1% cream, both approved by the United States Food and Drug Administration for treatment of persistent facial erythema of rosacea. In this article, the author discusses challenges related to the treatment of persistent facial erythema of rosacea and the use of a-agonist therapy. The author also discusses cases of worsening of facial erythema after the application of brimonidine, as well as briefly reviews recently reported clinical data on oxymetazoline...
July 2017: Journal of Clinical and Aesthetic Dermatology
keyword
keyword
41157
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"